Total Payments
$527,657
2024 Payments
$170,871
Companies
35
Transactions
701
Medicare Patients
3,237
Medicare Billing
$416,292
Payment Breakdown by Category
Other$358,177 (67.9%)
Consulting$106,770 (20.2%)
Travel$38,411 (7.3%)
Food & Beverage$24,197 (4.6%)
Education$101.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $358,027 | 121 | 67.9% |
| Consulting Fee | $106,770 | 36 | 20.2% |
| Travel and Lodging | $38,411 | 110 | 7.3% |
| Food and Beverage | $24,197 | 431 | 4.6% |
| Honoraria | $150.00 | 1 | 0.0% |
| Education | $101.75 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $293,721 | 271 | $0 (2024) |
| Insmed, Inc. | $149,984 | 207 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $49,168 | 75 | $0 (2024) |
| GENZYME CORPORATION | $13,957 | 21 | $0 (2024) |
| Grifols USA, LLC | $12,633 | 12 | $0 (2024) |
| Nabriva Therapeutics, plc | $1,784 | 2 | $0 (2022) |
| Merck Sharp & Dohme LLC | $1,502 | 2 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $502.86 | 20 | $0 (2024) |
| Inari Medical, Inc. | $494.84 | 3 | $0 (2022) |
| Genentech USA, Inc. | $481.85 | 10 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $170,871 | 162 | GlaxoSmithKline, LLC. ($87,813) |
| 2023 | $142,449 | 151 | GlaxoSmithKline, LLC. ($95,218) |
| 2022 | $92,152 | 116 | GlaxoSmithKline, LLC. ($66,200) |
| 2021 | $53,157 | 89 | Insmed, Inc. ($26,535) |
| 2020 | $25,248 | 46 | GlaxoSmithKline, LLC. ($14,584) |
| 2019 | $42,322 | 90 | Insmed, Inc. ($37,861) |
| 2018 | $1,002 | 32 | GlaxoSmithKline, LLC. ($314.79) |
| 2017 | $456.28 | 15 | Shire North American Group Inc ($144.12) |
All Payment Transactions
701 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Respiratory | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $449.96 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $179.20 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $123.49 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $306.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | Cash or cash equivalent | $13.13 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $122.55 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: RESPIRATORY | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | ERBE USA INC | VIO3 APC3 Cryo2 (Device) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: Pulmonology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $53.75 | General |
| 11/16/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $130.62 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $1,119.46 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $158.75 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 844 | 1,048 | $445,751 | $91,745 |
| 2022 | 16 | 833 | 997 | $433,030 | $94,321 |
| 2021 | 15 | 758 | 974 | $474,079 | $105,528 |
| 2020 | 16 | 802 | 1,131 | $624,898 | $124,698 |
Total Patients
3,237
Total Services
4,150
Medicare Billing
$416,292
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 105 | 187 | $75,507 | $25,468 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 137 | 174 | $53,039 | $16,054 | 30.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 25 | 68 | $86,768 | $12,268 | 14.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 63 | $28,037 | $6,190 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 48 | 48 | $21,143 | $5,533 | 26.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 100 | 102 | $20,502 | $4,486 | 21.9% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 99 | 101 | $20,604 | $4,147 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $12,606 | $3,974 | 31.5% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 29 | 29 | $17,634 | $3,194 | 18.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $16,584 | $2,607 | 15.7% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Facility | 2023 | 49 | 53 | $17,085 | $1,865 | 10.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 85 | 87 | $31,146 | $1,654 | 5.3% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 14 | 14 | $14,028 | $1,398 | 10.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 19 | $3,819 | $1,336 | 35.0% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 29 | 29 | $22,852 | $916.40 | 4.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 15 | 15 | $2,535 | $361.01 | 14.2% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 17 | 19 | $1,862 | $292.41 | 15.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 63 | 152 | $176,320 | $28,795 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 92 | 140 | $51,372 | $19,524 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 95 | 111 | $30,726 | $10,842 | 35.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $17,342 | $5,615 | 32.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $16,032 | $5,509 | 34.4% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 101 | 101 | $18,483 | $4,801 | 26.0% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 100 | 100 | $18,500 | $4,344 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 40 | 41 | $7,585 | $3,256 | 42.9% |
About Dr. Anas Hadeh, MD
Dr. Anas Hadeh, MD is a Pulmonary Disease healthcare provider based in Weston, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1437360187.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anas Hadeh, MD has received a total of $527,657 in payments from pharmaceutical and medical device companies, with $170,871 received in 2024. These payments were reported across 701 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($358,027).
As a Medicare-enrolled provider, Hadeh has provided services to 3,237 Medicare beneficiaries, totaling 4,150 services with total Medicare billing of $416,292. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location Weston, FL
- Active Since 05/24/2007
- Last Updated 04/24/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1437360187
Products in Payments
- Arikayce (Drug) $114,207
- AREXVY (Drug) $108,144
- NUCALA (Biological) $68,242
- TRELEGY ELLIPTA (Drug) $65,288
- FASENRA (Biological) $27,873
- TEZSPIRE (Biological) $19,926
- Xembify (Biological) $12,633
- DUPIXENT (Biological) $3,921
- Xenleta (Drug) $1,784
- FLOWTRIEVER CATHETER, S (Device) $494.84
- Xolair (Biological) $464.34
- OFEV (Drug) $403.19
- UPTRAVI (Drug) $316.84
- AIRSUPRA (Drug) $261.86
- FASENRA (Drug) $247.83
- ACTHAR (Biological) $242.30
- TYVASO (Drug) $241.49
- Yupelri (Drug) $219.68
- BREZTRI (Drug) $211.32
- ANORO (Drug) $167.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Weston
Franck Rahaghi, M.d, M.D
Pulmonary Disease — Payments: $1.8M
Pulmonary Disease $1.8M
David Zisman, Md, Ms, MD, MS
Pulmonary Disease — Payments: $170,415
Pulmonary Disease $170,415
Jinesh Mehta, M.d, M.D
Pulmonary Disease — Payments: $101,462
Pulmonary Disease $101,462
Samantha Gillenwater, Md, MD
Pulmonary Disease — Payments: $30,441
Pulmonary Disease $30,441
Ciro Rincon-Prieto, M.d, M.D
Pulmonary Disease — Payments: $5,096
Pulmonary Disease $5,096
Christopher Lau
Pulmonary Disease — Payments: $1,349
Pulmonary Disease $1,349